drugset
drugset / Trial / NCT05214066

Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

NCT05214066 ↗

Phase 2 Unknown 60 enrolled Chinese PLA General Hospital
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine the efficacy and safety of combined ATG #antithymocyte globulin # regimen (5mg/kg divided from day -5 to day -2) for aGVHD(acute graft-versus-host disease ) prophylaxis in matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT).

Timeline

Start
2019-02-01
Primary completion
2022-08-01
Completion
2022-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymoglobulin Protein / enzyme biologic 1 mg/kg —

Indications

acute graft versus host disease chronic graft versus host disease